Roka Bioscience

The story has been corrected to state that Roka's technology is based on transcription mediated amplification methods, not PCR technology.

NEW YORK (GenomeWeb) – Foodborne pathogen molecular diagnostics firm Roka Bioscience has filed with the US Securities and Exchange Commission to go public.

Roka Bioscience said Friday that it has secured $47.5 million in Series D financing to support the commercialization of its molecular food safety testing platform.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Roka Bioscience said after the close of the market on Friday that it has raised $27.5 million toward a $47.5 million Series D financing round.

The 2009 Gen-Probe spinoff has exclusive licensing rights to various Gen-Probe nucleic acid-based tests and instrumentation for use in industrial applications.

The firm was founded two years ago in order to commercialize the industrial assets of Gen-Probe and today its CEO said that it is on track to launch its first molecular assay for food safety testing later this year.

Millipore claims that its test, which incorporates transcription-mediated amplification technology developed by Gen-Probe offshoot Roka Bioscience, provides a few advantages over PCR-based Mycoplasma testing.

Gen-Probe is spinning off its industrial testing assets into a new, independently operated company. The spin off will continue Gen-Probe's collaborations with Millipore and GE Water.

Pages

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.